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Abstract: Peginesatide is a synthetic, dimeric peptide that is covalently linked to polyethylene 
glycol (PEG). The amino acid sequence of peginesatide is unrelated to that of erythropoietin 
(EPO) and is not immunologically cross-reactive with EPO. Peginesatide binds to and activates 
the human EPO receptor, stimulating the proliferation and differentiation of human red cell 
precursors in vitro in a manner similar to other EPO-stimulating agents (ESAs). In Phase II 
and III studies in dialysis and predialysis patients, peginesatide administered once monthly 
was as effective as epoetin alfa given thrice weekly (dialysis patients) or darbepoetin given 
once weekly (nondialysis patients), in correcting anemia of chronic kidney disease as well as 
maintaining hemoglobin within the desired target range. In the dialysis population, the reported 
side-effect profile of peginesatide was comparable to that known with other marketed ESAs. 
In the nondialysis studies, compared with those treated with darbepoetin, patients treated with 
peginesatide experienced a higher adverse-effect profile. Peginesatide is likely to be licensed 
for treatment of renal anemia in dialysis patients and not in nondialysis patients. Despite this 
limitation, peginesatide is likely to prove valuable in treating dialysis patients because of 
its infrequent mode of administration, thereby allowing for a reduced number of injections, 
with associated better compliance, reduced cold storage requirement, and improved stock 
  accountability. PEGylated therapeutic proteins can elicit immunological response to the PEG 
moiety of the therapeutic complex. Only long-term experience and post-marketing surveillance 
will address whether this immunological response will have any impact on the clinical efficacy 
or safety of peginesatide in clinical practice.
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Introduction
Prior to the introduction of recombinant human erythropoietin (rhuEPO) in clinical 
practice, many patients receiving dialysis were severely anemic and needed transfusions 
to maintain a hemoglobin level greater than 7 g/dL.1 Consequently, patients suffered 
many of the consequences of chronic anemia, mainly in terms of volume overload, 
hyperkalemia, iron overload, blood-borne infections, and allosensitization.2
The introduction of erythropoiesis-stimulating agents (ESAs) has changed the care 
of patients with kidney disease by increasing hemoglobin levels and thereby avoiding 
the need for transfusions. The first ESAs to be introduced were short-acting (eg, epoetin 
alfa and beta) and required administration three times a week. The introduction of dar-
bepoetin, a second-generation ESA and, more recently, Mircera (Hoffmann-La Roche, 
Basel, Switzerland), a third-generation ESA (EU only), both with extended duration 
of action, has led to less-frequent dosing with a comparable efficacy.3 All these ESAs 
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are derivates of the parent molecule, rhuEPO. The creation 
of a drug that is structurally different from rhuEPO, yet 
capable of stimulating erythropoiesis, could be an interesting 
therapeutic development. The benefit of such a development 
could be the elimination of the potential to induce immune 
response to rhuEPO and therefore compromise its action. In 
its most severe form, such an immune response could mani-
fest as pure red cell aplasia (PRCA), a severe form of anemia 
unresponsive to all the currently licensed ESAs, rendering 
affected patients transfusion-dependent. Such a development 
could also address other unmet needs in treating anemia in 
chronic kidney disease (CKD) patients.
Peginesatide, a drug capable of stimulating erythropoi-
esis, and likely to be licensed for clinical use in the near 
future, is the first ESA that bears no structural similarity to 
rhuEPO. This mini review will discuss the data available from 
Phase II and III clinical trials of peginesatide, focusing on its 
clinical use and safety profile, and will conclude by discuss-
ing its potential role in the field of management of anemia of 
CKD and possible uncertainties that may be associated with 
its use in clinical practice.
Peginesatide: structure  
and preclinical data
Peginesatide is a synthetic, dimeric peptide that is cova-
lently linked to polyethylene glycol (PEG). Its molecular 
weight ranges between 45.0 to 50.5 kDa.4 The amino acid 
sequence of peginesatide is unrelated to that of rhuEPO and 
is not immunologically cross-reactive with rhuEPO.4 This 
characteristic potentially reduces the risk of PRCA, and 
theoretically may provide a rescue treatment for patients 
affected by such condition. Peginesatide binds to and acti-
vates the human EPO receptor, stimulating the proliferation 
and differentiation of human red cell precursors in vitro in a 
manner similar to ESAs.5 A predictable, dose-related effect 
on reticulocyte and hemoglobin levels has been observed in 
rats and monkeys.6,7
Clinical efficacy
In a Phase I study to evaluate the safety and pharmacody-
namic effects of single, intravenous doses (0.025, 0.05, and 
0.1 mg/kg) of peginesatide in 28 healthy male volunteers, all 
doses were well tolerated, with safety profiles comparable 
to that of placebo. Peginesatide showed a dose-dependent 
increase in reticulocytes. The 0.1 mg/kg dose was associated 
with a statistically significant increase in hemoglobin from 
baseline compared with the placebo group. That effect was 
sustained for more than 1 month.4
Peginesatide: experience in correcting 
anemia in CKD patients not on dialysis
The efficacy of peginesatide in correcting anemia in CKD 
patients was demonstrated in a Phase II trial. Patients who 
were not on dialysis, and not receiving treatment with 
ESAs in the 12 weeks before study drug administration, 
were sequentially assigned to 1 of 10 cohorts that differed 
in starting peginesatide dose (different body weight-based 
or absolute doses), route of administration (intravenous or 
subcutaneous), and frequency of administration (every 4 or 
2 weeks). Across all cohorts, 96% of patients achieved a 
hemoglobin response. A dose-response relationship was evi-
dent for hemoglobin increase. Comparable subcutaneous and 
intravenous peginesatide doses produced similar hemoglobin 
responses. Rapid rates of hemoglobin rise and hemoglobin 
excursions . 1 g/dL tended to occur more frequently with 
once-fortnightly dosing than with once-monthly dosing. This 
study provided the first proof that peginesatide administered 
every 4 weeks can increase and maintain hemoglobin level 
in nondialysis CKD patients.8
Phase III studies have demonstrated that dialysis patients 
maintained on epoetin alfa can be switched successfully to 
once-monthly peginesatide (unpublished data).
In CKD patients not on dialysis, although once-monthly 
peginesatide was noninferior to darbepoetin alfa in both 
correction of anemia and maintenance of hemoglobin within 
target range, higher proportions of adverse events and   serious 
adverse events were observed in the peginesatide treatment 
group compared with the darbepoetin treatment group 
(unpublished data). The cause of such increased incidence 
in the peginesatide group compared with the darbepoetin 
group is unclear. But based on these results, peginesatide is 
likely to receive licensing approval only for the treatment 
of anemia in dialysis patients and not for CKD patients not 
on dialysis.
Correction of anemia in patients  
with pure red cell aplasia
Because anti-EPO antibodies have not been observed to 
cross-react with peginesatide,9,10 peginesatide was studied 
as a potential treatment in CKD patients with anti-EPO 
antibody-mediated PRCA.
In a Phase II, open-label, multiple-dose study to 
evaluate the ability of peginesatide administered monthly 
to increase and maintain hemoglobin levels in these 
  transfusion-dependent patients, 14 patients were treated 
with peginesatide for a median of 28 months. The median 
hemoglobin concentration increased from 9.0 g/dL 
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(with transfusion support in 12 out of 14 patients) before 
treatment, to 11.4 g/dL at the time of the last administration 
of peginesatide; transfusion requirements diminished within 
12 weeks after the first dose, after which 13 of the 14 patients 
no longer required regular transfusions.11
The level of anti-EPO antibodies declined over the 
course of the study and became undetectable in six patients. 
One patient who initially responded to treatment had a 
diminished hematologic response a few months later despite 
increased doses of peginesatide and required transfusions 
again; this patient was found to have antibodies against 
peginesatide.11
Antibody responses and clinical effects  
in clinical studies
Peginesatide differs from ESAs derived from human EPO 
in that it is a synthetic, dimeric peptide that does not share 
structural homology with human EPO. Among 139 patients 
enrolled in a Phase II study, two patients (1.4%) had detect-
able levels of peginesatide-specific neutralizing antibodies. 
Those two patients showed no evidence of de novo anti-EPO 
antibodies, and no new cases of PRCA were reported in any 
patient receiving peginesatide.8
Peginesatide: a role in the 
management of anemia in dialysis 
patients?
It is now over 20 years since rhuEPO was first used to treat 
anemic CKD patients. During this period, the market was 
dominated with recombinant human EPO or its derivatives. 
The imminent introduction of peginesatide to the anemia 
market provides an exciting opportunity to physicians and 
clinical researchers alike to use a drug that is structurally 
unrelated to EPO, yet capable of producing its desired thera-
peutic effects. There are several potential advantages to using 
an EPO mimetic agent to treat anemic CKD patients.
Peginesatide: a PEGylated EPO mimetic 
dipeptide
The conjugation of small proteins with PEG, or PEGylation, 
has become an increasingly common method of improving 
the half-life of biological products, mainly through reducing 
the urinary excretion of the molecule12 but also by reduc-
ing the enzymic degradation due to the increased steric bulk.1 
In addition, PEGylated biological products often exhibit a 
reduced affinity for the target receptor compared with the 
native precursor. This reduced affinity can lead to a lower 
elimination by target-mediated clearance mechanisms, and 
prolonged half-life of the PEGylated product. Finally, the 
addition of the PEG moiety can have beneficial effects on 
the immunological profile of a molecule by reducing the 
ability of the compound to raise antibodies in humans.13 All 
these characteristics make the development of peginesatide 
an attractive therapeutic alternative to other ESAs in the 
treatment of anemia in patients with CKD.
A novel peptide
Being structurally different from other licensed ESAs, 
  peginesatide may be ideally used whenever other ESAs 
cannot be used (eg, intolerance to therapeutic proteins, non-
neutralizing anti-EPO antibodies). Although not within its 
current license application, its use as a rescue therapy in 
patients with EPO-induced red cell aplasia may provide a 
marketing leverage over other available ESAs.
A long-acting preparation
The use of a long-acting ESA in treating anemia in dialysis 
patients provides a unique opportunity to create maximum 
value for patients and healthcare providers alike by reduc-
ing waste through improved quality, efficiency, and safety. 
A long-acting ESA may have the following potentials:
•	 It may offer more flexibility in ESA dosing and 
  administration compared with the existing shorter-acting 
preparations.
•	 It may release more time for health workers to treat more 
patients and attend to more complicated cases.
•	 Monthly administration would allow hospital   pharmacies 
to request the drug when needed, with little need for 
storage.
•	 The reduced number of injections (from 100–150 injections 
per patient year to 12 injections per patient year) may 
translate into a reduced need for cold storage capacity, 
reduced risk and asset-value loss in the case of cold stor-
age interruption, reduced wastage, and reduced number 
of missed doses.
•	 Once-monthly dosing may help address clinical 
  governance issues by facilitating accurate stock, 
  prescription, and administration reconciliation.
The use of peginesatide may provide  
the opportunity to reduce overall patient 
exposure to ESA
Preliminary post hoc analysis of Phase III studies of pegine-
satide in dialysis patients suggests that for patients receiv-
ing high epoetin doses at baseline (ie, prior to switch to 
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  peginesatide), the relative dose of peginesatide is   significantly 
lower than that for those receiving low epoetin doses at 
baseline (unpublished data). This suggests that, for patients 
requiring a high maintenance dose of epoetin, switching to 
peginesatide may provide the opportunity to reduce overall 
drug exposure without compromising therapeutic efficacy. 
Whether this may translate into a better outcome for patients 
may need further long-term trials to determine.
Peginesatide: residual uncertainties
Before peginesatide establishes itself as a therapeutic alter-
native to other licensed ESAs, it has to overcome a few 
challenges.
The position of ESA therapy  
in the current anemia market
The results of two large multicenter studies have suggested 
a possible association between high hemoglobin level and 
increased cardiovascular events in patients with CKD.14,15 
In addition, post hoc analyses of these studies suggests a 
direct association between ESA dose and survival in CKD 
patients.16,17 Becoming increasingly aware of these data, 
clinicians are actively trying to minimize ESA utilization, 
and to rely alternatively on parenteral iron therapy. This 
is compounded by the fact that national and international 
guidelines on anemia management have brought therapeutic 
target hemoglobin in ESA-treated patients to a lower level in 
response to the results of these multicenter studies.18,19
Price
As more ESAs are introduced into the ever-expanding anemia 
market, the marketing price of ESA products is being reduced 
by the pharmaceutical industry to maintain their position in 
the anemia market. This is particularly relevant in Europe, 
where several biosimilars have been in the market for over 
4 years now. This is also important given the current financial 
climate where healthcare providers are continually exploring 
new avenues to make health service delivery more afford-
able and cost-effective. Peginesatide has to be marketed at 
a price that allows it to compete with other well-established 
ESAs.
Restricted license
The drug is likely to be licensed for the treatment of renal 
anemia in chronic dialysis patients only. Based on the avail-
able safety data, Affymax (Palo Alto, CA) is not seeking 
marketing authorization for the treatment of renal anemia in 
patients not on dialysis. Given the fact that the majority of 
dialysis patients start ESA therapy before they start dialysis, 
patients may need to switch to peginesatide as they com-
mence renal replacement therapy. A peginesatide marketing 
campaign may need to establish a strong reason to convince 
stakeholders of the benefits of switching patients as they 
commence renal replacement therapy.
Peginesatide: just another ESA?
Although structurally different from rhuEPO, peginesatide 
acts in a mechanism similar to other ESAs available for 
clinical use (ie, via stimulation of EPO receptors), has to 
be administered parenterally, and possibly shares the same 
safety profile as other ESAs. Clinicians will ask for a con-
vincing case to switch patients from existing ESAs that have 
been in clinical practice for over a decade, with well over 
one million patient/year exposure and a well-documented 
safety profile,20 to the newly introduced peginesatide, with 
comparatively limited safety data and relatively limited 
information on clinical experience.
Compliance
With the use of long-acting ESA in treating chronic dialysis 
patients, there is a need to ensure a maximum compliance 
with ESA administration. In a cross-sectional study on UK 
dialysis patients, concordance (defined as receiving $90% 
of the prescribed dose) ranged from 24% to 33%.21 While 
missing a single injection of a short-acting ESA preparation 
may result in a transient reduction of the overall area under 
the curve of ESA blood level, missing a whole monthly ESA 
injection may translate into a more significant and protracted 
drop in the area under the curve, with possible consequences 
on hemoglobin levels. Therefore, for units contemplating the 
use of monthly ESA preparation for their dialysis preparation, 
a robust drug accountability/risk-management plan should 
be established to minimize the risk of missed dose, or of 
over- or underdosing. Nevertheless, it is also important here 
to note that the above study found that reduced frequency of 
administration was associated with fewer missed doses.
Metabolic fate of PEGylated ESA  
in CKD patients
The clearance via metabolism of the PEGs that are typically 
used to alter the pharmacokinetics of biological products 
(molecular weight of 5000 or greater)22,23 is likely to be 
  insignificant. This is because the metabolism of PEG is 
molecular weight-dependent, with high-molecular-weight 
PEGs (.4000) showing less metabolism.24 The major route 
of   elimination of PEG occurs through passive glomerular 
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  filtration and is dependent on molecular weight.24 Human 
excretion balance studies have shown that 86% and 96% of 
PEG 1000 and 6000 were excreted in the urine 12 hours after 
intravenous administration.25,26 These data raise questions about 
the metabolic fate of peginesatide as well as other PEGylated 
ESAs in patients with CKD, particularly in dialysis patients, 
many of whom have a markedly diminished or even zero 
glomerular filtration rate. In these patients, PEG is likely to 
accumulate in tissues in patients who receive long-term treat-
ment with the drug. In fact, there are no systematic long-term 
studies that show: (1) whether PEG is excreted completely or 
partly remains in the body, (2) where it is accumulated, and 
(3) its effects at the sites of accumulation.27 Ideally, the fate of 
any pharmaceutical product should be addressed via relevant 
pharmacokinetic studies, but this is impossible to achieve 
with PEGylated proteins in clinical practice. This is due to 
several reasons; first, identifying metabolites of PEG will be 
difficult because the PEGs used always have polydispersed 
molecular weight.22 Second, subtle changes in mass due to 
metabolism will be undetectable by mass spectrometry because 
of the range of molecular weights present in the PEG. Also, 
it has been shown that PEG can suppress ionization in a mass 
  spectrometer.28 In addition, humans and animals are   commonly 
exposed to PEG via a variety of environmental sources, which 
means that it is likely that human plasma, urine, and other 
body fluids contain a range of PEGs and PEG metabolites. 
When the trace doses of most PEGylated biological products 
are combined with the ubiquitous “contamination” likely to 
be seen in animals and humans, it is unlikely that the approach 
to metabolite identification would be successful.27 Therefore, 
only post-marketing long-term surveillance will be able to 
address the long-term effects of the use of PEGylated ESAs 
in patients with CKD.
PEGylated ESA: a possible immune 
reaction?
It has been shown that PEG, which is not supposed to 
show any opsonization, can in fact induce specific as 
well as   nonspecific recognition by the immune system, 
thereby   leading to a response of the body to intravenously 
  administered PEG formulations.
Anti-PEG antibodies
Animal studies have clearly shown that some PEGylated 
proteins can elicit antibody formation against PEG.29–31 
This anti-PEG response can accelerate the clearance of 
PEGylated proteins.32–34 In humans, PEG antibodies can be 
produced and may limit therapeutic efficacy, and may even 
reduce tolerance of PEG–asparaginase in patients with acute 
lymphoblastic leukemia,35 and of pegloticase in patients 
with chronic gout.36,37 Of major importance is the recent 
finding of a 22% to 25% occurrence of PEG antibodies in 
350 healthy blood donors.35,38 It has been suggested that this 
increase is most likely due to greater exposure to PEG and 
PEG-containing compounds in cosmetics, pharmaceuticals, 
and processed food products.35 These authors recommend 
that patients should be screened for pre-existing anti-PEG 
and monitored for the development of anti-PEG throughout 
the course of treatment with any PEG containing agent.35 It is 
not clear whether this immunological response to PEG may 
have contributed to the unfavorable hematological response 
observed among nondialysis CKD patients treated with 
peginesatide compared with those treated with darbepoetin 
in Phase III studies. In addition, the available clinical data 
on peginesatide did not evaluate the prevalence of anti-PEG 
antibody response among patients treated with peginesatide. 
It is hoped that this aspect will be addressed in the upcom-
ing publication of the results of Phase III clinical trials of 
peginesatide in patients with CKD.
PEG-induced complement activation
It has been shown that PEG, administered at doses equiva-
lent to those used to bind therapeutic proteins, can gener-
ate complement activation products in human serum on 
a time scale of minutes via activation of the alternative 
  complement pathway. PEG-induced complement activation 
has been reported to cause anaphylaxis.39,40 An immediate 
hypersensitivity reaction (HSR) in 5% to 10% of treated 
patients was shown for different PEG-containing liposomal 
carriers.27 Complement activation with subsequent HSR 
was demonstrated with 99mTc-labeled 2 kDa methoxy-
PEG-liposomes for the treatment of Crohn’s disease.41 The 
PEGylated liposome formulation of doxorubicin used in 
anticancer therapy also caused HSR in up to 25% of patients, 
despite pretreatment with corticosteroids and antihistamines, 
and without prior sensitization.39 This PEG-induced effect 
may be of particular relevance among some groups of CKD 
patients who are known to have impaired alternative comple-
ment activation as a possible mechanism of initiation and 
progression of their kidney disease, such as patients with 
mesangiocapillary glomerulonephritis/dense deposit disease 
or certain forms of hemolytic uremic syndrome.
Conclusion
Peginesatide is a novel peptide with no structural similarity to 
rhuEPO, yet capable of stimulating erythropoiesis in patients 
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with anemia of CKD. It is likely to gain a license for treating 
anemia in CKD patients who are on dialysis. Peginesatide may 
also be used as a rescue therapy in patients who develop EPO-
induced PRCA. Once licensed, long-term clinical experience 
may provide insights on its potential as an ESA-minimizing 
agent in patients requiring large maintenance ESA doses. 
Peginesatide will probably have the same hematological safety 
profile as other available ESAs. PEG present in the therapeu-
tic PEGylated proteins may contribute to the adverse-event 
profile, probably through activation of anti-PEG antibodies 
and complement consumption via the alternative pathway. 
Only long-term clinical experience/pharmacovigilance data 
will determine the exact place of peginesatide in the field of 
anemia management in patients with CKD.
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